Renalytix Plc (AIM:RENX)
2.650
0.00 (0.00%)
Jul 27, 2026, 4:01 PM GMT
Renalytix Market Cap
Renalytix has a market cap or net worth of 11.58 million as of July 27, 2026. Its market cap has decreased by -51.77% in one year.
Market Cap
11.58M
Enterprise Value
11.28M
Revenue
2.45M
Ranking
n/a
PE Ratio
n/a
Stock Price
2.65
ChartMarket Cap Chart
Since November 6, 2018, Renalytix's market cap has decreased from 64.58M to 11.58M, a decrease of -82.07%. That is a compound annual growth rate of -19.94%.
| Date | Market Cap | % Change |
|---|---|---|
| Jul 27, 2026 | 11.58M | -55.08% |
| Dec 31, 2025 | 25.78M | -27.58% |
| Dec 31, 2024 | 35.60M | 129.87% |
| Dec 29, 2023 | 15.49M | -71.47% |
| Dec 30, 2022 | 54.30M | -87.89% |
| Dec 31, 2021 | 448.32M | 27.67% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro |
| Nov 6, 2018 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| AstraZeneca | 196.51B |
| GSK plc | 76.44B |
| Haleon | 32.02B |
| Smith & Nephew | 9.59B |
| Cambridge Cognition Holdings | 15.13M |
| RUA Life Sciences | 14.89M |
| CelLBxHealth | 14.49M |
| Fusion Antibodies | 13.44M |